Aug 6, 2026 04:05PM
Jul 28, 2026 08:31AM
Jul 28, 2026 08:30AM
Jun 29, 2026 07:02AM
Jun 29, 2026 07:00AM
Jun 23, 2026 06:50AM
Jun 11, 2026 07:02AM Relmada appoints Michael Quirk as senior advisor for sepranolone program
Jun 11, 2026 07:00AM
May 12, 2026 04:05PM
May 5, 2026 07:00AM
Mar 19, 2026 04:01PM
Mar 13, 2026 02:49PM
Mar 9, 2026 08:31AM
Mar 9, 2026 07:01AM Relmada reports 12-month data for bladder cancer drug NDV-01
Mar 9, 2026 07:00AM
Mar 2, 2026 06:05AM
Jan 12, 2026 07:02AM
Jan 12, 2026 07:00AM
Dec 22, 2025 12:49AM
Dec 21, 2025 08:00PM
Dec 3, 2025 07:30AM Relmada presents NDV-01 bladder cancer data at urologic meeting
Dec 3, 2025 07:30AM
Nov 13, 2025 04:01PM
Nov 4, 2025 07:01AM
Nov 4, 2025 07:01AM
Oct 7, 2025 07:30AM
Oct 7, 2025 07:30AM
Sep 16, 2025 09:00AM Relmada regains compliance with NASDAQ minimum bid price requirement
Sep 16, 2025 09:00AM
Sep 10, 2025 07:15AM
Sep 10, 2025 07:15AM
Aug 7, 2025 04:05PM
Jul 15, 2025 08:02AM
Jul 15, 2025 08:00AM
Jun 17, 2025 07:00AM Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology
May 12, 2025 04:01PM
Apr 28, 2025 01:39PM
Apr 28, 2025 01:38PM
Apr 27, 2025 09:00AM
Apr 24, 2025 08:00AM
Apr 14, 2025 08:41AM
Apr 14, 2025 07:30AM Relmada Therapeutics To Present NDV-01 Data at AUA2025
Mar 27, 2025 04:05PM
Mar 25, 2025 07:32AM
Mar 25, 2025 07:30AM
Feb 6, 2025 07:30AM
Feb 6, 2025 07:30AM
Jun 18, 2024 08:31AM
Jun 18, 2024 08:30AM Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry
Jan 9, 2023 08:01AM

328,564 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All